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Bridges II: The Law-STEM Alliance &
Next Generation Innovation
Jacob S. Sherkow*
What incentives would foster more collaboration between the law and
STEM lifelds, in either academic or business/entrepreneurial settings?
There are already significant incentives for collaboration between law
and STEM: commercializing technologies, creating architectures for data-
sharing, and funding for interdisciplinary research, for example.
1 The problem is getting legal and STEM academics to think seriously
about these virtues at the beginning of their work rather than as an
afterthought. In particular, and despite the hype surrounding patent disputes
like CRISPR, many scientists do not think about the intellectual property
issues surrounding their work until late in the research process.2 For some,
encouraging scientists to think about these issues in the course of their work
has the potential to taint the "purity" of scientific research, however defined.3
But even if one views the legal incentives to conduct STEM research
negatively, it's important to think about how to manage such incentives, even
if the decision is made to forgo such rights or give them away.4
Perhaps the best way to foster law-STEM collaborations is to simply
create spaces for such work. Many scientific journals, for example, have
been excellent at publishing legal academics' work on the intersection
between law and science.' But there appears to be little of the reverse: law
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1 See, e.g., Jacob S. Sherkow, Cancer's IP, 96N.C. L. REV. (forthcoming 2018),
https://papers.ssm.com/sol3/papers.cfm?abstractid=2928241 [https://perma.cc/GXA3 -6WB5]
(discussing these virtues in the context of cancer research).
2 Sharon Begley, Broad Institute Prevails in Heated Dispute over CRISPR Patents, STAT NEWS
(Feb. 15, 2017), https://www.statnews.com/2017/02/15/crispr-patent-ruling/ [https://perma.cc/5DCT-
KJQ5] (describing the disconnect between patent law and "how much of the science world has viewed
[the scientists'] work").
3 Michael Eisen Patents are Destroying the Soul ofAcademic Science, IT Is NOT JUNK (Feb. 20,
2017), http://www.michaeleisen.org/blog/?p=1981 [https://perma.cc/UUY5-MQV7].
4 See Brian Owens, Montreal Institute Going "Open" to Accelerate Science, SCIENCE (Jan. 21,
2016), http://www.sciencemag.org/news/2016/0 1/montreal-institute-going-open-accel-erate-science
[https://perma.cc/45FK-A7V5].
5 See, e.g., Eli Y. Adashi & I. Glenn Cohen, Going Germline: MitochondrialReplacement as a Guide
to Genome Editing, 164 CELL 832 (2016); Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter
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reviews, and the format of traditional law review articles, are less than
conducive to housing the work of scientists.6 Hosting conferences and
symposium aimed at bringing together legal academics and STEM
researchers-like Northwestern's recent Bridges II conference-are
superlative attempts to encourage true interdisciplinary work between the
two fields. These are good starts. But to truly encourage a cross-pollination
of fields, such spaces need to be established with more regularity and
directed more consistently. In practical terms, such events could be used to
create clearinghouses for a variety of problems in the legal architecture of
scientific research. Deceptively simple questions-like how to build and
license a data pool-are resolved on almost exclusively ad hoc basis.' While
such experimentation has been wonderful at producing a diversity of models,
without further sustained collaboration between law and STEM, they remain
daunting for an average scientist to implement.
Provide an example ofa situation in which a Law-STEM collaboration
aided a project or where the lack of collaboration between these two
disciplines impeded a project.
Two biological repositories, AddGene and Hetionet, provide
contrasting examples of how law-STEM collaborations-or the lack
thereof-have contributed to STEM projects' success or failure. AddGene,
for one, is a sterling example of collaboration and innovation between legal
and scientific fields.' The organization is a not-for-profit repository of
biological materials "dedicated to making it easier for scientists to share."'
In particular, AddGene houses "a high-quality library of published [DNA
modules] for use in research and discovery," allowing scientists to contribute
their constructs to and borrow constructs from AddGene under a standard,
nonnegotiable license: the Uniform Biological Material Transfer Agreement
Innovation? The Anticommons in Biomedical Research, 280 SCIENCE 698 (1998); Jacob S. Sherkow,
Pursuit ofProfit Poisons Collaboration, 532 NATURE 172 (2016).
6 One notable exception to this dearth of collaborative opportunities is a recent UCLA Law Review
PULSE symposium on the future of various scientific and technological developments. See PULSE
Symposium 2016, UCLA L. REv. http://www.uclalawreview.org/pulse-symposium-2016/
[https://perma.cc/LWX7-25C7] (last visited Jun. 4, 2017). That symposium featured, among other
contributions, a fascinating piece-with Bluebooked footnotes-by Christopher Kelty, a professor at
UCLA's Institute for Society and Genetics, and not an attorney. See Christopher Kelty, Two Fables,
64 UCLA L. REV. DISC. 488 (2016).
See, e.g., Simon Oxenham, Legal Maze Threatens to Slow Data Science, 536 NATURE, Aug. 3,
2016, at 16 (describing the development of Hetionet, a metadatabase of gene-drug interactions).
8 ADDGENE, https://www.addgene.org [https://perma.cc/65YU-K-X8G] (last visited Jun. 4, 2017).
AboutAddGene, ADDGENE, https://www.addgene.org/mission/ [https://perma.cc/QUG4-MVW7]
(last visited Jun. 4, 2017).
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(UBMTA). 1 o Scientists at participating institutions who wish to deposit a
construct with AddGene, or borrow one from the service, simply sign and
go. For scientific researchers-and for their parent institutions-this process
has numerous advantages: it allows researchers to outsource the day-to-day
tasks of sharing to AddGene; it cuts license negotiating time down to zero
by using a universal, take-it-or-leave-it agreement; it provides a central
clearing house to track the results of borrowing-itself a separate, potential
object of study; and it frees researcher time by vouching for samples' quality,
purity, and identity. But for all of these goods, it bears repeating that the heart
of AddGene is collaborative, legal innovation: the standard, non-negotiable
UBMTA. This boilerplate, legal document-created as joint enterprise of
industry and both legal and STEM academia in 199511-is what allows
AddGene to operate with fluidity. Deploying it in connection with an
independent biological repository is one of the greater triumphs of
collaboration between law and science.
By contrast, Hetionet, is a sad example of one of its failures. Hetionet
survives as a meta-database: a database comprised of other data sources on
the effect of drugs on certain illnesses and genetic conditions.1 2 As originally
reported in Nature in 2016, Hetionet's founder, data-scientist Daniel
Himmelstein, attempted to create Hetionet by aggregating data from larger,
independent databases.1 3 Such an effort would have made data-mining for
connections between drugs and disease substantially more powerful. But
Hetionet's largest problems were not technical but legal: Himmelstein had
difficulty getting licenses from each of the smaller databases to use in his
larger service. Indeed, some potentially important and significant databases
were not ultimately included in Hetionet simply because of vagaries of the
licensing process. To date, Hetionet remains hampered by these licensing
issues.1 4 Some recent programs-like the Cancer Moonshot-are aimed at
addressing precisely these types of issues for future projects. 15 But without
direct collaboration among scientists and legal academics, success will
ultimately remain difficult.
10 Technology Transfer Information, ADDGENE, https://www.addgene.org/techtransfer/
[https://perma.cc/AW29-FF32] (last visited Jun. 4, 2017).
11 See Arti Kaur Rai, Regulating Scientific Research: Intellectual Property Rights and the Norms of
Science, 94 Nw. U. L. REV. 77, 113 (1999) (discussing the history of the UBMTA).
12 Hetnets in Biomedicine, HET.IO, http://het.io [https://perma.cc/4S6L-VJTS].
13 Oxenham, supra note 7, at 16.
14 Id.
15 Sherkow, supra, note 1, (manuscript at 20-21) (discussing the Moonshot's data-sharing goal).
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